Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap

H R Stagg, H-A Hatherell, M C Lipman, Ross J Harris, I Abubakar

Research output: Contribution to journalArticlepeer-review


Treatment guidance for non-multidrug-resistant (MDR) rifampicin-resistant (RMP-R) tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis of the randomised controlled trial (RCT) data behind such guidelines to identify the most efficacious treatment regimens. Ovid MEDLINE, the Web of Science and EMBASE were mined using search terms for TB, drug therapy and RCTs. Despite 12 604 records being retrieved, only three studies reported treatment outcomes by regimen for patients with non-MDR RMP-R disease, preventing meta-analysis. Our systematic review highlights a substantial gap in the literature regarding evidence-based treatment regimens for RMP-R TB.

Original languageEnglish
Pages (from-to)866-9
Number of pages4
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number7
Publication statusPublished - Jul 2016


  • Antibiotics, Antitubercular/therapeutic use
  • Biomedical Research/methods
  • Drug Resistance, Bacterial
  • Evidence-Based Medicine
  • Humans
  • Microbial Sensitivity Tests
  • Predictive Value of Tests
  • Professional Practice Gaps/methods
  • Randomized Controlled Trials as Topic
  • Rifampin/therapeutic use
  • Tuberculosis/diagnosis


Dive into the research topics of 'Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap'. Together they form a unique fingerprint.

Cite this